Citi Sticks To These Pharma Stocks Amid Trump's 25% Tariff Plans
The US President Donald Trump intending to impose 25% tariff on pharmaceuticals imports has added to the uncertainty for the Indian pharma stocks, Citi Research...
The US President Donald Trump intending to impose 25% tariff on pharmaceuticals imports has added to the uncertainty for the Indian pharma stocks, Citi Research...
Read More
Other Stories in Business
- Gulf War veteran executed for 1998 quadruple murder despite claims of mental illness
- Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth
- Connecting Asia's startup ecosystem
- Connecting Asia's startup ecosystem
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- From a Joke That Went Too Far to Radical Ideology – How Did the Memecoin Paradigm Change
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- L3Harris Technologies Stock: A Steady Course In A Changing World (NYSE:LHX)
- Business First Bancshares, Inc. (BFST) Q1 2025 Earnings Call Transcript
